Background: The qualitative transcriptional characteristics, the within-sample relative expression orderings (REOs) of genes, are highly robust against batch effects and sample quality variations. Hence, we develop a qualitative transcriptional signature based on REOs to predict the biochemical recurrence risk of prostate cancer (PCa) patients after radical prostatectomy. Methods: Gene pairs with REOs significantly correlated with the biochemical recurrence-free survival (BFS) were identified from 131 PCa samples in the training data set. From these gene pairs, we selected a qualitative transcriptional signature based on the within-sample REOs of gene pairs which could predict the recurrence risk of PCa patients after radical prostatectomy.
| INTRODUCTION
Prostate cancer (PCa) is the second most frequently diagnosed malignant tumor in men worldwide, with the highest morbidity rates in the developed countries. 1, 2 In China, PCa has the most rapid rise of incidence along with the increases of the aging population and the implementation of advanced detection services in recent decades. 3 The standard method to treat localized PCa patients is radical prostatectomy, while approximately 20% to 40% of patients will suffer from biochemical recurrence in 10 years. 4, 5 The prostatespecific antigen (PSA) level is an important indicator of biochemical recurrence for localized and locally advanced PCa after radical prostatectomy. 6 Nevertheless, some PCa patients with poor prognoses have a low PSA level. 7, 8 The currently available clinicalpathological features, such as the Gleason grade group, clinical and pathological stage and surgical margin, 9, 10 are unable to provide accurate predictions for biochemical recurrence. [11] [12] [13] Thus, it is crucial to develop an accurate prognostic signature to predict the recurrence risk for PCa patients after radical prostatectomy.
High-throughput microarray and RNA-sequencing technologies facilitate researchers developing transcriptional prognostic signatures for PCa patients. [14] [15] [16] However, most of the reported transcriptional signatures depend on risk threshold values summarized from the quantitative expression measurements of the signature genes, [14] [15] [16] which are easily vulnerable to the measurement variations from batch effects introduced by laboratory conditions, reagent lots, and personal differences. In fact, subtle quantitative values of gene expression measurements are quite error-prone. 17 Data normalization methods for removing batch effects might even exacerbate the batch problems 18, 19 and these methods are not suitable for individualized analysis of clinical application. On the contrary, the within-sample relative expression orderings (REOs) of genes that are the qualitative features of transcription have been proved to be robust against experimental batch effects and differences in probe designs of different platforms. 20, 21 The within-sample REO is a promising feature for building robust classifiers, for example top-scoring pair (TSP) 22 and k-TSP 23 with existing R packages. 24, 25 Besides, the within-sample REO can be robustly analyzed individual sample without normalization, which is suitable for individualized application in clinical practice.
More importantly, our previous studies have demonstrated that different from the signatures based on quantitative expression measurements of the signature genes, the REOs-based qualitative signatures are rather insensitive to the tumor cell percentage difference of specimen sampled from different parts of the same tumor, 26 the inescapably partial RNA degradation 27, 28 and amplification bias of low-input RNA samples. 29 Based on these unique advantages of the within-sample REOs, we have developed the qualitative REOs-based signatures for predicting the prognosis of breast cancer, 30, 31 colorectal cancer, 32 gastric cancer, 33 liver cancer, 34 and lung cancer. 35 Thus, it is worthwhile to develop a qualitative prognostic signature for PCa patients after radical prostatectomy.
In this study, a qualitative REOs-based signature consisting of 74 gene pairs, named as 74-GPS, was developed to predict the recurrence risk of PCa patients using 131 samples in the training data set. A sample was assigned as high-risk when at least 37 gene pairs of the 74-GPS voted for high risk; otherwise, low risk. This signature was validated in six independent datasets produced by different platforms, totally including 660 fresh-frozen (FF) samples and 106 formalin-fixed paraffin-embedded (FFPE) samples. Using the multiomics data of PCa samples from The Cancer Genome Atlas (TCGA), we analyzed the distinct transcriptomic, epigenetic, and genomic differences between the two prognostic groups. The results might be helpful for understanding the mechanisms of different prognoses and guiding the management for PCa patients.
| MATERIALS AND METHODS

| Data collection and data preprocessing
Data for PCa were downloaded from the Gene Expression Omnibus 36 (GEO, http://www.ncbi.nlm.nih.gov/geo/) and TCGA (http://cancergenome.nih.gov/) database. A total of 791 FF samples from six datasets and 106 FFPE samples from the GSE54460 data set with BFS data were analyzed, as described in Table 1 . These datasets were measured by different platforms, including single-channel microarray, dual-channel microarray, and next-generation sequencing (NGS). For datasets measured by the Affymetrix platform, a robust multi-array average (RMA) algorithm was used to process the raw mRNA expression data (.CEL files). 37 For datasets measured by the Illumina platform and the Stanford Functional Genomics Facility dual-channel platform, the processed data were directly used.
The level 3 mRNA-seq profiles, DNA methylation profiles, and copy number profiles used in the study were obtained from cBioPortal (http://www.cbioportal.org/), 38, 39 which the gene expression values, the methylation values (β) of the CpG sites or the copy number alternation status of regions had already been mapped to Entrez gene IDs. We directly downloaded these processed data.
Overall, 20 436 genes for gene expression data, 16 182 genes for DNA methylation data and 23 286 genes for copy number data were analyzed in this study, respectively. The level 2 gene mutation data were downloaded from TCGA portal. A discrete mutation profile including 11 249 genes only with the nonsynonymous mutations were generated. The voting rule was as follows: a patient was classified into the highrisk group when at least 50% of the gene pairs voting for high risk;
| Survival analysis
| Development of the qualitative signature
otherwise, the patient was classified into the low-risk group. The R-codes for developing the REOs-based signature were available in Supporting Information Methods.
| Analysis of epigenomic and genomic data
The RankCompV2 method, which is insensitive to batch effects, 43 was used to identify differentially expressed genes (DEGs) between the high-risk and low-risk groups of PCa samples. the Wilcoxon ranksum test was used to identify differentially methylated genes (DMGs). Fisher's exact test was used to detect genes whose frequencies of copy number alteration or mutation were significantly different between two prognostic groups of TCGA samples.
| Direction concordance scores
If k genes were overlapped between two DEGs lists identified from two datasets, of which s genes showed the same dysregulated direction (both up-or downregulated in the high-risk group compared to the lowrisk group), then the direction concordance score was computed as s/k.
Similarly, if k genes were overlapped between two DMGs lists identified from two datasets, of which s genes showed both hyper-or hypomethylated in the high-risk group compared with the low-risk group, then the direction concordance score was computed as s/k.
For k DMGs, if s genes were upregulated (or downregulated) and T A B L E 1 Description of the datasets used in this study Abbreviations: FF, fresh-frozen; FFPE, formalin-fixed paraffin-embedded; NA, not available; PSA, prostate-specific antigen.
correspondingly hypomethylated (or hypermethylated), the direction concordance score was computed as s/k. This score was used to calculate the reproducibility of DEGs identified from multiple independent datasets and the consistency between DEGs and DMGs. The cumulative binomial distribution model 44 was used to evaluate whether the case of observing a direction concordance score of s/k is random:
where p e = 0.5 is the probability of one gene having the concordant dysregulated direction in two lists of genes by chance.
| Functional enrichment analysis
The gene categories for functional enrichment analysis were performed on the Kyoto Encyclopedia of Genes and Genomes. 45 The hypergeometric distribution model 46 was applied to determine the significance of biological pathways enriched by genes of interest. The Benjamini and
Hochberg procedure 47 was used to estimate the FDR. Statistical analysis was carried out with the R software package version 3.5.1.
| RESULTS
| Development of the qualitative REOs-based signature
The general workflow of this study is described in Figure 1 . Total, 131 FF PCa samples measured by the GPL10264 platform (Table 1) Figure 2C ). The signature was also verified in the other three validation datasets with 92, 89, and 36 FF samples, respectively.
Each group of patients at the low-risk had significantly longer BFS than the group of patients at the high-risk in all datasets ( Figure 2D-F) .
Notably, 106 FFPE samples in the data set GSE54460 were successfully stratified into two different prognostic groups: 91 patients at the low-risk group had a significantly better BFS than 15 patients at the high-risk group (HR = 2.68, 95% CI: 1.40-5.14, P = 6.82 × 10 −3 , C-index = 0.57; Figure 2G ). As we know, FFPE samples always suffer RNA degrade during the process of preparation and storage, which hampers the clinical application of quantitative transcriptional signatures. 27, 48 The multivariate Cox regression analysis was also performed in the validation datasets. The results showed that the signature remained significantly associated with patients' BFS in the datasets PC332, PC111, PC92, and PC89 after adjusting the available clinic pathological factors. The detailed information was shown in Figure 4 and Table S2 ). These results suggested that the distinct transcriptional characteristics of the two prognostic groups were highly reproducible in the independent datasets.
With FDR < 10%, functional enrichment analysis for the 1250
DEGs identified from TCGA samples in the data set PC332 revealed that the genes upregulated in the high-risk group were significantly enriched in pathways associated with cell proliferation, such as the PI3K-Akt signaling pathway and the TGF-beta signaling pathway, whereas the downregulated genes were significantly enriched in 
Note: Gene pair votes for high-risk when Gene A has a higher expression level than Gene B in a sample.
metabolic pathways, such as fatty acid degradation pathway and glutathione metabolism pathway (hypergeometric distribution model, FDR < 10%, Table S3 ). These results indicated that the tumor cells in the high-risk patients might grow faster than that in the low-risk patients and experience dysregulated metabolism, which led to poor prognosis of PCa patients. 49 
| Distinct genomic characteristics of the two prognostic groups
The 331 samples with copy number alteration data in the data set PC332 were divided into 160 high-risk samples and 171 low-risk Table   S4 and S6.
In the data set PC160, 98 samples and 62 samples with copy number variation data were classified into the high-risk prognostic group and the low-risk prognostic group, respectively. A total of 4893 genes had significantly higher copy number alteration frequencies in the high-risk group than in the low-risk group (Fisher exact test, P < 5%), with a direction concordance score of 74.47%
(2138/2871) in the datasets PC332. And the direction concordance score of amplification with upregulation in the high-risk group was 82.26% (51/62). All the direction concordance scores were also unlikely happened due to chance (shown in Table S4 and S6).
The results observed in the datasets PC332, PC131, and PC160
implied that these copy number alterations, especially amplification, may cause reproducibly transcriptional alterations between different prognostic groups.
Using Fisher's exact test with P < .1, 84 genes whose mutation frequencies tended to be different were detected between the 160 high-risk samples and the 171 low-risk samples with somatic mutation data in the data set PC332 (Table S7 ). Impressively, all of the 84 genes had higher mutation frequencies in the high-risk group than in the lowrisk group, which was unlikely to happen due to chance (binomial distribution test, P < 2.2 × 10 −16 ). In the data set PC160, 12 genes whose mutation frequencies tended to be different were detected between the 97 high-risk and the 62 low-risk samples with somatic mutation data (Fisher's exact test, P < .1). In both the data set PC160 and PC332, TP53 was with significantly higher mutation frequencies in the high-risk group than in the low-risk group. It has been reported that TP53 mutation is correlated with metastasis and poor prognosis of PCa patients. [51] [52] [53] Functional enrichment analysis showed that these 84 mutation genes were significantly enriched in focal adhesion and PI3K-Akt signaling pathways (hypergeometric distribution model, FDR < 10%), suggesting that mutation-induced alternation of genes in these pathways might lead a poor outcome of PCa patients.
| DISCUSSION
In this study, we developed a qualitative transcriptional signature, 74-GPS, to predict the recurrence risk of PCa patients after radical prostatectomy, which was validated in six independent datasets produced by different platforms, including a total of 660 FF and 106 FFPE samples. The further multiomics data analyses showed that the distinct transcriptomic, epigenetic, and genomic landscapes between the high-risk and low-risk groups might be helpful to understand the mechanisms of different prognoses and prescribe more specific and proper treatments for PCa patients. Consistent with our previous study, 34 the qualitative REOs-based prognostic signature is highly robust against experimental batch effects and differences in probe designs of different platforms. Besides, the signature can be readily applied at an individualized level without data normalization, which is more reliable and practical than quantitative signatures for risk prediction. 54 At present, most of the clinical tissue samples are fixed in FFPE blocks, [55] [56] [57] and stored in hospitals and tissue banks, which is a huge and precious resource for clinical research. 58 Nevertheless, FFPE samples are generally considered unreliable for gene expression analysis because of RNA degradation during preparation and storage.
As shown in our previous study, 27 Table S1 and Figure S1 ), it is necessary to collect an additional data set of independent samples in our future work to validate our signature. For the sake of more reliable prediction under some circumstances, the 74-GPS could be combined with preoperative PSA and surgical margins to predict the biochemical recurrence for PCa patients.
The multiomics analysis of TCGA samples played an essential role in uncovering the underlying molecular mechanisms of determining different prognoses of PCa patients after radical prostatectomy. For example, gene PDGFRB in the PI3K-Akt signaling pathway, which was upregulated with concordant hypomethylation in the high-risk group, can regulate cell growth, division, and migration 59, 60 and is correlated with bone metastases and biochemical recurrence of PCa patients. 61, 62 In addition, gene THBS1 in the TGF-beta signaling pathway, which was upregulated with consistent hypomethylation alteration in the high-risk group, has been reported to be positively associated with the invasion of PCa and the recurrence of PCa patients after radical prostatectomy. 63 These results provided evidence that the tumor cells of high-risk patients own faster growth and stronger migration abilities, which result in poorer prognoses.
According to the National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer patients after radical prostatectomy, 64 PSA measurements should be performed every 6
to 12 months and a digital rectal examination (DRE) is recommended annually for the first 5 years. For PCa patients assigned as high risk by the signature, we suggest that more close follow-ups, such as PSA testing every 3 months and DRE every 6 months for the first 5 years, maybe better to detect disease progression timely. This study may be helpful to guide management and improve prognoses for PCa patients after radical prostatectomy.
| CONCLUSION
In conclusion, the qualitative REO-based 74-GPS is a robust 
